L
270.29
-1.23 (-0.45%)
| Previous Close | 271.52 |
| Open | 268.42 |
| Volume | 357,031 |
| Avg. Volume (3M) | 803,308 |
| Market Cap | 22,461,100,032 |
| Price / Earnings (TTM) | 26.53 |
| Price / Earnings (Forward) | 15.65 |
| Price / Sales | 1.69 |
| Price / Book | 2.64 |
| 52 Weeks Range | |
| Earnings Date | 17 Feb 2026 |
| TTM Dividend Yield | 0.27% |
| Profit Margin | 5.55% |
| Operating Margin (TTM) | 9.94% |
| Diluted EPS (TTM) | 8.68 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Quarterly Earnings Growth (YOY) | -6.70% |
| Total Debt/Equity (MRQ) | 79.13% |
| Current Ratio (MRQ) | 1.84 |
| Operating Cash Flow (TTM) | 1.63 B |
| Levered Free Cash Flow (TTM) | 967.92 M |
| Return on Assets (TTM) | 4.18% |
| Return on Equity (TTM) | 8.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Labcorp Holdings Inc. | Bullish | Bullish |
AIStockmoo Score
1.9
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Value |
| % Held by Insiders | 0.36% |
| % Held by Institutions | 96.44% |
| 52 Weeks Range | ||
| Median | 319.00 (18.02%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 06 Feb 2026 | 319.00 (18.02%) | Buy | 277.20 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Jan 2026 | Announcement | Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026 |
| 14 Jan 2026 | Announcement | Labcorp Declares Quarterly Dividend |
| 13 Jan 2026 | Announcement | Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk |
| 08 Jan 2026 | Announcement | Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs |
| 08 Jan 2026 | Announcement | NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp |
| 30 Dec 2025 | Announcement | Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference |
| 02 Dec 2025 | Announcement | Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp |
| 24 Nov 2025 | Announcement | Labcorp Appoints Victor Bulto to Board of Directors |
| 19 Nov 2025 | Announcement | Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research |
| TTM Dividend Yield | 0.27% |
| 4Y Average Dividend Yield | 0.97% |
| Payout Ratio | 33.22% |
| Expected Next Dividend Payment | Mar 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 27 Feb 2025 | 08 Jan 2025 | 12 Mar 2025 | 0.72 Cash |
| 26 Nov 2024 | 10 Oct 2024 | 13 Dec 2024 | 0.72 Cash |
| 29 Aug 2024 | 25 Jul 2024 | 13 Sep 2024 | 0.72 Cash |
| 24 May 2024 | 11 Apr 2024 | 12 Jun 2024 | 0.72 Cash |
| 26 Feb 2024 | 12 Jan 2024 | 13 Mar 2024 | 0.72 Cash |
| 07 Nov 2023 | 12 Oct 2023 | 12 Dec 2023 | 0.72 Cash |
| 07 Aug 2023 | 13 Jul 2023 | 08 Sep 2023 | 0.72 Cash |
| 17 May 2023 | 06 Apr 2023 | 08 Jun 2023 | 0.72 Cash |
| 22 Feb 2023 | 12 Jan 2023 | 13 Mar 2023 | 0.72 Cash |
| 16 Nov 2022 | 12 Oct 2022 | 09 Dec 2022 | 0.72 Cash |
| 17 Aug 2022 | 14 Jul 2022 | 09 Sep 2022 | 0.72 Cash |
| 18 May 2022 | 07 Apr 2022 | 09 Jun 2022 | 0.72 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 0.720 | 1 | 0.29 |
| 2024 | 2.88 | 4 | 1.26 |
| 2023 | 2.88 | 4 | 1.27 |
| 2022 | 2.16 | 3 | 1.07 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |